ArticleBone marrow transplantation2021

Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.

Emily C Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.